Global Acute Repetitive Seizures Market Predicted to Reach $5.4 Billion, Expanding at 11.4% CAGR Through 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Does the Market Size of the Acute Repetitive Seizures Market in 2029 Compare With That of 2025?
The acute repetitive seizures market size has grown rapidly in recent years. It will grow from $3.13 billion in 2024 to $3.5 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rise in epilepsy prevalence, increasing awareness of seizure management, growth in use of rescue medications, improving diagnostic capabilities, and expansion of healthcare access.
The acute repetitive seizures market size is expected to see rapid growth in the next few years. It will grow to " $5.4 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing demand for non-invasive treatments, increasing investment in epilepsy research, rising adoption of wearable seizure monitors, expansion of telemedicine in neurology, and government initiatives for epilepsy care. Major trends in the forecast period include adoption of AI in seizure prediction, integration of digital health solutions, expanding clinical trials for innovative treatments, development of gene therapies for epilepsy, and development of novel drug formulations.
Get your free report sample today:
Which Key Dynamics Are Contributing to the Expansion of the Acute Repetitive Seizures Market?
The rising prevalence of neurological disorders is expected to propel the growth of the acute repetitive seizures market going forward. Neurological disorders are health conditions that affect the brain, nerves, or spinal cord, causing problems with movement, speech, thinking, or body functions. The rising prevalence of neurological disorders is primarily due to an aging population, as older adults are more susceptible to degenerative brain changes, increasing the risk of conditions like Alzheimer's disease, Parkinson's disease, and stroke. Acute repetitive seizures contribute to the progression of neurological disorders by increasing the risk of neuronal damage, cognitive decline, and long-term complications, necessitating early intervention to prevent worsening outcomes. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, which is projected to rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the acute repetitive seizures market.
Which Key Segments Are Included in the Acute Repetitive Seizures Market Analysis?
The acute repetitive seizuresmarket covered in this report is segmented –
1) By Drug Type: Benzodiazepines; Antiepileptic Drugs; Barbiturates; Other Drug Types
2) By Route Of Administration: Intranasal; Rectal; Oral; Other Routes Of Administrations
3) By End User: Hospitals; Clinics; Home Care Settings
Subsegments:
1) By Benzodiazepines: Diazepam; Lorazepam; Midazolam; Clonazepam; Alprazolam
2) By Antiepileptic Drugs: Levetiracetam; Phenytoin; Valproate; Carbamazepine; Lamotrigine
3) By Barbiturates: Phenobarbital; Primidone
4) By Other Drug Types: Corticosteroids; Intravenous Immunoglobulins (IVIG); Cannabinoids
What New Market Trends Are Emerging in the Acute Repetitive Seizures Market?
Major companies operating in the acute repetitive seizures market are focusing on developing innovative formulations such as benzodiazepine buccal film to improve drug absorption, provide rapid seizure relief, and enhance patient convenience. Benzodiazepine buccal film is a thin, dissolvable film containing a benzodiazepine medication placed inside the cheek for rapid absorption through the oral mucosa. It helps manage acute repetitive seizures by delivering the drug quickly into the bloodstream, reducing seizure duration and frequency. For instance, in December 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical company, announced that its product, Libervant (diazepam) buccal film, received seven years of orphan drug exclusivity (ODE) from the U.S. Food and Drug Administration (FDA). Libervant is used for the acute treatment of intermittent, stereotypic episodes of frequent seizures, including seizure clusters and acute repetitive seizures. It is a buccally administered dissolvable film of diazepam. This benzodiazepine enhances the effects of gamma-aminobutyric acid (GABA) to reduce seizure activity by acting as a central nervous system depressant.
Who Are the Key Strategic Players in the Acute Repetitive Seizures Market Ecosystem?
Major companies operating in the acute repetitive seizures market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bausch Health US LLC. , UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Endo International plc, Lupin Limited, Amneal Pharmaceuticals LLC, Aquestive Therapeutics Inc., Neurelis Inc., Grupo Ferrer Internacional S.A., UpsherSmith Laboratories LLC , Aculys Pharma Inc.
Get the detailed acute repetitive seizures market report today
What Are the Fastest-Growing Regions in the Acute Repetitive Seizures Market?
North America was the largest region in the acute repetitive seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute repetitive seizures market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment